Minispasm (Hyoscine Butylbromide)

Minispasm (Hyoscine Butylbromide) acts on smooth‑muscle receptors in the gastrointestinal system to reduce spasm and pain.

• Abdominal cramps: provides rapid relief of painful intestinal muscle contractions.
• Irritable bowel syndrome: lessens episodic cramping and discomfort associated with IBS.
• Biliary colic: eases spasms of the biliary ducts during gallstone attacks.
• Renal colic: reduces ureteral smooth‑muscle spasm caused by kidney stones.
• Gastrointestinal spasm: diminishes generalized GI tract spasm and associated pain.

• Hyoscine Butylbromide exerts its antispasmodic effect by competitively blocking muscarinic (M1‑M3) receptors on peripheral smooth‑muscle cells, especially in the gastrointestinal tract. This antimuscarinic blockade prevents acetylcholine‑mediated contraction, leading to relaxation of the smooth muscle, reduced spasm, and alleviation of associated pain.

Hyoscine Butylbromide is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Dry mouth
• Blurred vision
• Constipation
• Urinary retention
• Tachycardia
• Dizziness

Serious or Rare Side Effects

• Allergic reactions such as rash, angioedema, or anaphylaxis
• Severe hypotension
• Paralytic ileus
• Life‑threatening tachyarrhythmias
• Acute glaucoma exacerbation

Before prescribing Minispasm, clinicians should consider patient‑specific factors and monitor for potential complications.

• Glaucoma: avoid in patients with narrow‑angle glaucoma as anticholinergic effects may increase intra‑ocular pressure.
• Urinary retention: use with caution in individuals with prostatic hypertrophy or bladder outlet obstruction.
• Myasthenia gravis: may exacerbate muscle weakness; assess risk before use.
• Elderly patients: start with the lowest effective dose and monitor for anticholinergic burden.
• Hypersensitivity: discontinue if any allergic reaction occurs.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Hyoscine Butylbromide may interact with other medications that possess anticholinergic or synergistic pharmacodynamic properties.

Major Interactions (Avoid)

• Other anticholinergics (e.g., atropine, scopolamine): additive anticholinergic effects may cause severe dryness, tachycardia, or urinary retention.
• Tricyclic antidepressants: increased risk of anticholinergic toxicity.
• Antipsychotics with strong anticholinergic activity: may potentiate central and peripheral side effects.
• Cholinesterase inhibitors (e.g., donepezil): antagonistic action may reduce therapeutic benefit of the inhibitor.
• Antihistamines with anticholinergic properties: heightened risk of dry mouth, blurred vision, and constipation.

Moderate Interactions (Monitor Closely)

• Antihypertensives: possible additive hypotensive effect.
• Opioids: combined use may increase constipation.
• Antidiabetic agents: anticholinergic action may mask hypoglycemia symptoms.
• Certain antibiotics (e.g., quinolones): may increase risk of QT prolongation when combined with tachycardia.
• Antifungal azoles: monitor for any unexpected increase in anticholinergic side effects.